Skip to content

Study · In vitro (cells) · mouse · 2012

2 results

Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes.

Gilliam LA, Moylan JS, Patterson EW, Smith JD, Wilson AS, Rabbani Z, Reid MB

American journal of physiology. Cell physiology21 Sept 2011Cited by 119 (Europe PMC)

PMID21940668 (opens in a new tab)PMCIDPMC3328915 (opens in a new tab)DOI10.1152/ajpcell.00217.2011 (opens in a new tab)PepBankPUB-21940668
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In C2C12 myotubes exposed to doxorubicin, SS31 inhibited expression of the ROS-sensitive atrogin-1/MAFbx.

    In plain wordsIn muscle cells in lab tests, SS31 reduced a muscle-breakdown gene turned on by doxorubicin.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseAtrogin-1/MAFbx expression after doxorubicin
    Study

    mousen: not reported in source

    C2C12 myotubes exposed to doxorubicin
    Comparator
    Doxorubicin without SS31
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treating myotubes with SS31 (opposes mitochondrial ROS) inhibited expression of ROS-sensitive atrogin-1/MAFbx
    1 context sentence
    Summary · context
    We tested this hypothesis by exposing differentiated C2C12 myotubes to doxorubicin (0.2 μM).
  2. 02LabIn vitro (cells)Mechanism

    In C2C12 myotubes exposed to doxorubicin, SS31 protected against doxorubicin-stimulated catabolism.

    In plain wordsIn muscle cells in lab tests, SS31 protected against muscle breakdown caused by doxorubicin.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseDoxorubicin-stimulated catabolism
    Study

    mousen: not reported in source

    C2C12 myotubes exposed to doxorubicin
    Comparator
    Doxorubicin without SS31
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treating myotubes with SS31 (opposes mitochondrial ROS) inhibited expression of ROS-sensitive atrogin-1/MAFbx and protected against doxorubicin-stimulated catabolism.
    1 context sentence
    Summary · context
    We tested this hypothesis by exposing differentiated C2C12 myotubes to doxorubicin (0.2 μM).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.